Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Quirke

Showing results (231-240 of 249) with videos related to

Pageof 25
Sort By:
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|November 26, 2013
The English national low rectal cancer development programme: key messages and future perspectivesB J Moran, T Holm, G Brannagan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2025
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II populationJ F Seligmann, D Morton, F Elliott, et al.
International Journal of Colorectal Disease|January 31, 2014
The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery : proceedings of a consensus conferenceK Søndenaa, P Quirke, W Hohenberger, et al.
Oncogene|August 29, 2006
Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumorsK Jong, E Marchiori, A van der Vaart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2025
Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528]J F Seligmann, D Morton, F Elliott, et al.
The British Journal of Surgery|September 20, 2011
Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer, O C Shihab, F Taylor, et al.
West African Journal of Medicine|January 12, 2013
KRAS and BRAF mutations in Nigerian colorectal cancersF B Abdulkareem, L A Sanni, S D Richman, et al.
Heliyon|September 28, 2018
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)R Glynne-Jones, M R Hall, A Lopes, et al.
BMC Cancer|October 24, 2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectumR Glynne-Jones, N Hava, V Goh, et al.
Virchows Archiv : an International Journal of Pathology|September 20, 2008
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programJ H J M van Krieken, A Jung, T Kirchner, et al.
Pageof 25

Showing results (231-240 of 249) with videos related to

Sort By:
Pageof 25
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|November 26, 2013
The English national low rectal cancer development programme: key messages and future perspectivesB J Moran, T Holm, G Brannagan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2025
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II populationJ F Seligmann, D Morton, F Elliott, et al.
International Journal of Colorectal Disease|January 31, 2014
The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery : proceedings of a consensus conferenceK Søndenaa, P Quirke, W Hohenberger, et al.
Oncogene|August 29, 2006
Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumorsK Jong, E Marchiori, A van der Vaart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2025
Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528]J F Seligmann, D Morton, F Elliott, et al.
The British Journal of Surgery|September 20, 2011
Relevance of magnetic resonance imaging-detected pelvic sidewall lymph node involvement in rectal cancer, O C Shihab, F Taylor, et al.
West African Journal of Medicine|January 12, 2013
KRAS and BRAF mutations in Nigerian colorectal cancersF B Abdulkareem, L A Sanni, S D Richman, et al.
Heliyon|September 28, 2018
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)R Glynne-Jones, M R Hall, A Lopes, et al.
BMC Cancer|October 24, 2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectumR Glynne-Jones, N Hava, V Goh, et al.
Virchows Archiv : an International Journal of Pathology|September 20, 2008
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programJ H J M van Krieken, A Jung, T Kirchner, et al.
Pageof 25